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Abstract
Objective: To establish the upper limits for changes in FEV1, slow vital capacity (SVC), FVC, and inspiratory 
capacity (IC) after placebo administration in patients with airflow obstruction. Methods: One hundred and two 
adults with airflow obstruction (FEV1 = 62 ± 19% of predicted) were included in the study. All of the participants 
performed SVC and FVC maneuvers before and after the administration of placebo spray. The changes in FEV1, 
SVC, FVC, and IC were expressed as absolute values, percentage of change from baseline values, and percentage 
of predicted values, 95% CIs and 95th percentiles being calculated. Factor analysis was performed in order 
to determine how those changes clustered. Results: Considering the 95% CIs and 95th percentiles and after 
rounding the values, we found that the upper limits for a significant response were as follows: FEV1 = 0.20 L, 
FVC = 0.20 L, SVC = 0.25 L, and IC = 0.30 L (expressed as absolute values); FEV1 = 12%, FVC = 7%, SVC = 10%, 
and IC = 15% (expressed as percentage of change from baseline values); and FEV1 = 7%, FVC = 6%, SVC = 7%, 
and IC = 12% (expressed as percentage of predicted values). Conclusions: In patients with airflow obstruction, 
IC varies more widely than do FVC and SVC. For IC, values greater than 0.30 L and 15% of change from the 
baseline value can be considered significant. For FVC, values greater than 0.20 L and 7% of change from 
the baseline value are significant. Alternatively, changes exceeding 0.20 L and 7% of the predicted value can 
be considered significant for FEV1 and FVC. On factor analysis, spirometric parameters clustered into three 
dimensions, expressing changes in flows, volumes, and dynamic hyperinflation.
Keywords: Respiratory function tests; Spirometry; Bronchospirometry.
Resumo
Objetivo: Estabelecer os limites superiores para mudanças em VEF1, capacidade vital lenta (CVL), CVF e capacidade 
inspiratória (CI) após o uso de placebo em pacientes com obstrução ao fluxo aéreo. Métodos: Cento e dois 
adultos com obstrução ao fluxo aéreo (VEF1 = 62 ± 19% do previsto) foram incluídos neste estudo. Todos os 
participantes realizaram manobras de CVL e CVF antes e depois do uso de spray de placebo. As mudanças em 
VEF1, CVL, CVF e CI foram expressas em valores absolutos, porcentagem de variação em relação aos valores 
basais e porcentagem dos valores previstos, e foram calculados os IC95% e os percentis 95. A análise fatorial 
foi realizada a fim de determinar como essas alterações se agrupavam. Resultados: Considerando os IC95% 
e percentis 95 e após o arredondamento dos valores, obtivemos os seguintes limites superiores para resposta 
significante: VEF1 = 0,20 L, CVF = 0,20 L, CVL = 0,25 L e CI = 0,30 L (em valores absolutos); VEF1 = 12%, 
CVF = 7%, CVL = 10% e CI = 15% (em porcentagem de variação em relação aos valores basais) e VEF1 = 7%, 
CVF = 6%, CVL = 7% e CI = 12% (em porcentagem dos valores previstos). Conclusões: Em pacientes com 
obstrução ao fluxo aéreo, a CI apresenta maior variabilidade do que a CVF e a CVL. Para a CI, valores maiores 
que 0,30 L e 15% de variação em relação ao valor basal devem ser considerados significantes. Para CVF, valores 
maiores que 0,20L e 7% de variação em relação ao valor basal são significantes. Alternativamente, alterações 
de mais de 0,20 L e 7% do previsto no VEF1 e na CVF devem ser consideradas significantes. Na análise fatorial, 
os parâmetros espirométricos se agruparam em três dimensões, expressando mudanças no fluxo, volume e 
hiperinsuflação dinâmica.
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discontinued the use of short- and long-
acting β2 agonists (for ≥ 12 h and for ≥ 24 h, 
respectively) and of short- and long-acting 
theophylline preparations (for ≥ 24 h and for 
≥ 48 h, respectively). The patients were not 
required to discontinue the use of corticosteroids. 
The diagnosis of asthma or COPD was based on 
medical records made by specialists.
All of the study participants gave written 
informed consent, and the study protocol was 
approved by the local research ethics committee.
A total of 102 adults with airflow obstruction 
(asthma, COPD, or both) performed SVC maneuvers 
and, subsequently, FVC maneuvers. All patients 
had been stable in the last 30 days. Airflow 
obstruction was characterized by an FEV1/FVC 
ratio below the 5th percentile of the predicted 
value.
The spirometric tests were performed with a 
SensorMedics spirometer (Vmax229d; SensorMedics, 
Yorba Linda, CA, USA), which was calibrated daily. 
All SVC and FVC measurements were performed 
in accordance with the ATS/ERS criteria,(11) SVC 
being assessed during an expiratory maneuver.
A minimum of three acceptable SVC 
measurements were obtained. The difference 
between the highest SVC value and the second 
highest SVC value was < 0.150 L. For SVC, 
the largest value obtained from at least three 
acceptable maneuvers was recorded. For IC, at 
least three acceptable maneuvers were performed. 
The difference between the largest IC value and 
the second largest IC value was < 0.100 L. For 
IC, the values derived from the largest SVC 
were reported. The reference values for forced 
spirometry and IC were those reported in studies 
conducted in Brazil.(12,13) Within 15 min after 
the administration of four sprays of placebo, all 
tests were repeated in the same order, and the 
same acceptability and reproducibility criteria 
were applied.
General data are expressed as mean ± SD. 
The spirometric changes occurring after placebo 
administration are expressed as follows: absolute 
(post-baseline) values; percentage of change from 
baseline values (post-baseline × 100/baseline); 
and percentage of predicted values (post-baseline 
× 100/predicted).
The distribution of absolute changes induced 
by placebo was tested for normality by the 
Kolmogorov-Smirnov test and the Shapiro-Wilk 
test, as well as by analysis of normality plots, 
Introduction
In patients with airflow obstruction, changes 
in spirometric values after bronchodilator use 
are indicative of reversibility if they exceed the 
natural variability. On the basis of two landmark 
studies,(1,2) first the American Thoracic Society 
(ATS)(3) and later the ATS/European Respiratory 
Society (ERS)(4) issued statements in which they 
recommended that an absolute change of 200 mL 
and a relative change of 12% from baseline 
values be used in order to classify bronchodilator 
response as significant. Those values have also 
been reported as being indicative of significant 
changes in FVC after bronchodilator use,(1,4) being 
widely used.
Changes occurring after bronchodilator use 
can also be expressed in terms of the percentage 
of predicted values.(5) In two studies,(6,7) FEV1 
values higher than 6.0% were recommended.(6,7) 
In one of those studies,(7) an FVC value of 6.0% 
was recommended.
The relief of dyspnea and the increase in 
exercise performance after bronchodilator use 
in patients with airflow obstruction are due to 
a reduction in lung hyperinflation, as evidenced 
by increased inspiratory capacity (IC), increased 
vital capacity, or both.(8-10) To our knowledge, a 
small, single-center study(6) is the only study in 
which the limits of variation in IC after placebo 
administration were evaluated.(6) Although studies 
have suggested a cut-off point for IC based on 
a relevant increase in exercise performance,(9,10) 
it remains to be shown whether such values 
exceed the normal variability.
Changes in spirometric parameters after 
bronchodilator use can express variations in 
flow, volume, or both. The objective of the 
present study was to establish the upper limits 
for changes in slow vital capacity (SVC) and FVC 
after placebo administration in a large sample 
of patients with airflow obstruction, as well as 
to determine how those parameters clustered 
on factor analysis.
Methods
The present study was conducted in a referral 
pulmonary function laboratory in the city of 
São Paulo, Brazil.
All of the patients who were found to have 
obstructive disease were asked to return to the 
laboratory for further spirometry after having 
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On one-sample analysis, there was no evidence 
of any learning effect, the mean changes after the 
administration of placebo being nonsignificantly 
different from zero.
Table 2 shows the means, 95% CIs, and 95th 
percentiles for SVC, IC, FVC, and FEV1 after the 
administration of placebo, in terms of absolute 
values, percentage of change from baseline values, 
and percentage of predicted values. After rounding 
the values derived from these two methods, we 
obtained significant values for changes in the 
spirometric parameters under study (Table 3).
Spearman’s test revealed no significant 
correlation between changes in the spirometric 
parameters and their initial values (data not 
shown). Similarly, there were no correlations 
between changes in the spirometric parameters 
and age or between changes in the spirometric 
parameters and height.
Significant correlations were found between 
changes in FEV1 and changes in FVC (rs = 0.62; 
p < 0.001), between changes in SVC and changes 
in FVC (rs = 0.40; p < 0.001), and between changes 
in SCV and changes in IC (rs = 0.22; p = 0.017). 
By factor analysis, three factors were selected 
from the scree plot, explaining 92.5% of the 
total variance of changes after the administration 
of placebo. The first factor included changes 
in FEV1 and FVC, the second factor included 
the skewness coefficient, the kurtosis coefficient, 
extreme values, and outliers being assessed.(14) 
Outliers were not excluded from the analysis. 
Although the variations in SVC and IC showed 
normal distribution, the variations in FEV1 and 
FVC did not. The upper limits were calculated 
by 95th percentiles and 95% CIs.
The correlations of the different expressions of 
spirometric changes after placebo administration 
with anthropometric variables were determined 
by Spearman’s test. A two-tailed t-test was used 
for between-group comparisons.
For factor analysis, a correlation matrix was 
constructed, and the principal components were 
derived. A correlation coefficient > 0.30 was 
considered significant. Factors with an eigenvalue 
> 1 on principal component analysis were included 
in varimax rotation. For the final model, a scree 
plot was employed for factor selection, and 
three factors were retained. The next step was 
to construct a new factor matrix in order to 
examine the weight assigned to each variable 
per factor.
All statistical analyses were performed with the 
IBM SPSS Statistics software package, version 17.0 
(IBM Corporation, Armonk, NY, USA). Values of 
p < 0.05 were considered statistically significant.
Results
The clinical and spirometric data before the 
administration of placebo are shown in Table 1. 
Patient age ranged from 25 years to 80 years. 
Females predominated, as did patients with a 
diagnosis of asthma. In 17, 35, and 50 of the 
patients, respectively, FEV1 was ≤ 40% of the 
predicted value, 40–59% of the predicted value, 
and ≥ 60% of the predicted value.
There were differences between asthma and 
COPD patients in terms of the baseline percentage 
of predicted FEV1 (FEV1%). In the 64 patients with 
asthma, FEV1% was 65.3 ± 18.5, compared with 
54.1 ± 19.8 in the 34 COPD patients (t = 2.78; 
p = 0.006). However, the absolute variation in 
FEV1 after the administration of placebo was 
similar between the two groups of patients: 
−0.043 ± 0.122 mL in the patients with asthma 
and −0.009 ± 0.133 mL in those with COPD 
(t = 1.29; p = 0.20).
There were no differences between males 
and females in terms of the absolute changes 
in FEV1 (−0.045 ± 0.147 mL vs. −0.043 ± 0.147 
mL; t = 1.50; p = 0.124).
Table 1 - Clinical data and pulmonary function test 
results before the administration of placebo in 102 
patients with airflow obstruction.
Variable Result
Gender 
Male, n 39
Female, n 63
Age (years), mean ± SD 55 ± 11
Smoking status
Nonsmoker, n 50
Former smoker, n 42
Current smoker, n 10
Diagnosis 
COPD, n 34
Asthma, n 64
COPD and asthma, n 4
FEV1/FVC% (% of predicted) mean ± SD 56 ± 12
VC (% of predicted), mean ± SD 89 ± 17
FVC (% of predicted), mean ± SD 88 ± 17
FEV1 (% of predicted), mean ± SD 62 ± 19
IC (% of predicted), mean ± SD 83 ± 18
IC: inspiratory capacity.
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• What is the best way to express the changes 
occurring after medication use?
• What is the threshold that correlates with 
clinically significant outcomes?
Because it has the greatest sensitivity, the 
lowest variability, and the best reproducibility, FEV1 
is the most widely used spirometric parameter.(7) 
The ATS and the ERS proposed FEV1 and FVC 
increases of at least 0.20 L and of 12% of change 
from baseline values(4) on the basis of two studies.
(1,2) One of those studies evaluated the changes 
occurring after the administration of placebo in 
40 patients.(1) The 95% CI for FEV1 was 0.18 L 
when expressed in absolute values and 12.3% 
when expressed as percentage of change from 
baseline values. In the present study, these values 
were 0.19 L and 12.3%, respectively, and, when 
derived from the 95th percentile, 0.16 and 12.7%. 
In patients with low FEV1 values, the change in 
FEV1 after bronchodilator use commonly exceeds 
the limit of 12% of change from the baseline value. 
Therefore, it has been suggested that absolute 
and relative changes should be considered when 
evaluating the bronchodilator response. In the 
same study,(1) the upper limits for FVC were 0.34 L 
(absolute value) and 14.9% (percentage of change 
from the baseline value). In the present study, the 
FVC values derived from the 95% CI were 0.20 L 
and 7.3%, whereas those derived from the 95th 
percentile were 0.23 L and 6.5%. After rounding 
these values, we propose that the upper limits 
changes in SVC and FVC, and the third factor 
included changes in IC only (Table 4).
Discussion
In the present study, we propose upper limits 
for random short-term variations in parameters 
assessed by SVC and FVC maneuvers in a sample 
of patients with airflow obstruction. The variations 
in FEV1 were found to be the same as those 
found in previous studies. However, values for 
variations in FVC, when expressed as percentage 
of change from baseline values, were lower. This 
is the first study to derive values for changes in 
SVC and IC from a large sample.
Regarding the use of bronchodilators in a 
pulmonary function laboratory setting,(7) some 
questions remain:
• What are the most appropriate parameters 
to express bronchodilator response?
Table 2 - Mean variations, 95% CIs, and 95th percentiles for the absolute values, percentage of change from 
baseline values, and percentage of predicted values for spirometric parameters after placebo administration.
Parameter 
Absolute % of change from baseline % of predicted
Mean 95% CI
95th 
percentile
Mean 95% CI
95th 
percentile
Mean 95% CI
95th 
percentile
SVC −0.030 0.237 0.222 −0.890 9.5 7.5 −0.920 7.4 6.0
IC −0.006 0.283 0.317 0.034 14.1 15.4 −0.114 11.2 12.5
FVC −0.012 0.198 0.227 −0.283 7.3 6.5 −0.213 6.3 5.6
FEV1 −0.020 0.192 0.159 −0.796 12.3 12.7 −0.549 7.3 7.4
SVC: slow vital capacity; and IC: inspiratory capacity.
Table 3 - Significant variations for absolute values, percentage of change from baseline values, and percentage 
of predicted values for spirometric parameters after placebo administration.
Variation Absolute % of change from baseline % of predicted
SVC 0.25 10 7
IC 0.30 15 12
FVC 0.20 7 6
FEV1 0.20 12 7
SVC: slow vital capacity; and IC: inspiratory capacity.
Table 4 - Rotated component matrix for variations in 
spirometric parameters after placebo administration.
Parameter
Component
1 2 3
FEV1 0.935  
FVC 0.866 0.304  
SVC  0.976  
IC   0.994
SVC: slow vital capacity; and IC: inspiratory capacity.
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the administration of placebo in patients with 
airflow limitation, such as those investigated in 
the present study. In individuals without lung 
disease, FEV1 increases by less than 10% after 
bronchodilator use.(1,18,19) This cut-off point has 
been used for distinguishing between asthma 
and COPD patients in some studies.(20,21) However, 
this limit can be exceeded in some patients with 
COPD, especially if a combination of beta-agonists 
and anticholinergic agents is used.(22)
Hyperinflation is a physiological change that 
is characteristic of many patients with COPD. 
Airway obstruction leads to progressive air 
trapping during exhalation, as well as leading 
to hyperinflation. These changes result in reduced 
resting IC, increased work of breathing, and lower 
exercise tolerance.(8,9) Dynamic hyperinflation has 
been shown to be an independent predictor of 
decreased daily physical activity and mortality due 
to respiratory failure in patients with COPD.(23)
Bronchodilators reduce hyperinflation at rest 
and during exercise.(8-10) It is possible that patients 
with COPD who do not show a significant response 
to bronchodilators as assessed by flow (FEV1) 
will show a significant lung volume response as 
assessed by increased SVC and IC.(24) Increased IC 
has been associated with decreased hyperinflation 
and improved exercise tolerance.(8-10) Many studies 
involving different classes of bronchodilators 
have shown associations among increased 
IC, improved exercise tolerance, and reduced 
dyspnea in COPD patients.(25) However, changes 
in IC after placebo administration are poorly 
characterized. In a study involving 26 patients 
with asthma or COPD, the proposed limit for IC 
changes after placebo administration was a 9% 
increase from baseline values or 220 mL.(6) In 
two studies, an increase of more than 0.3 L in IC 
was associated with a significant improvement 
in exercise tolerance in patients with COPD.(9,10) 
In the present study, IC increases of more than 
15% in relation to the baseline values, of more 
than 12% in the predicted values, and of 0.3 L 
were found to constitute the upper limit for IC 
after the administration of placebo, values that 
are similar to those found in those studies.(9,10) 
For SVC, increases of more than 0.25 L, of more 
than 10% in relation to baseline values, or of 
more than 7% in the predicted values can be 
considered significant.
Bronchodilator responses can be categorized as 
flow responses or volume responses. When post-
be set at 0.20 L and 7%. The ATS and the ATS/
ERS(3,4) have stated that the variations in FVC 
should be the same as those in FEV1, probably on 
the basis of the expected short-term variability 
in FEV1 and FVC in spirometric maneuvers. 
Although the upper limit for absolute changes 
in FVC found in the present study is similar to 
those suggested by the ATS, the values for the 
percentage of change from baseline values are 
much lower. This will increase the sensitivity of 
FVC for detecting changes in lung function in a 
pulmonary function laboratory setting. In another 
study,(2) 150 patients with obstructive disease 
underwent two spirometric tests, 20 minutes 
apart. The increases in FEV1 and FVC required 
in order to exclude a random variation by 95% 
CI were 0.16 L and 0.33 L, respectively. In a 
more recent study, FEV1 and FVC variations were 
evaluated after the administration of placebo in 
98 patients with COPD.(7) The upper limit was 
found to be 0.18 L for FEV1 and 0.28 L for FVC.
The most common ways of expressing the 
bronchodilator response are absolute changes, 
percentage of change from baseline values, and 
percentage of predicted values. Measurements 
based on predicted values have the best 
reproducibility and are the least dependent 
on baseline values.(5) The values derived in the 
present study suggest that increases ≥ 7% in 
the predicted FVC and FEV1 values exceed the 
natural variability and can therefore be considered 
significant. For the sake of the reproducibility of 
the maneuvers, we believe that changes ≥ 0.20 L 
should also be present in order to characterize 
a significant response to bronchodilator use.
The bronchodilator response evaluated by FEV1 
has few, if any, clinical implications for COPD. 
The bronchodilator response varies according 
to the setting.(15) The lack of response in a 
laboratory setting does not translate to a lack 
of clinical response to bronchodilators or inhaled 
corticosteroids, as evaluated by short-term relief 
of dyspnea, long-term relief of dyspnea, improved 
quality of life, improved exercise capacity, and 
changes in FEV1.
(9,10,16,17)
Two types of studies have been used in order 
to derive cut-off points intended to characterize 
a significant bronchodilator response. Post-
bronchodilator variations can be considered 
significant if they exceed those observed in 
individuals without lung disease or if they 
exceed the spontaneous variation observed after 
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obstruction. However, there were no differences 
between the patients with asthma and those 
with COPD in terms of the variations in the 
parameters studied, and there were no correlations 
between FEV1% and the variation in FEV1 after 
the administration of placebo.
In conclusion, we established cut-off points for 
changes in parameters derived from SVC and FVC 
maneuvers performed after the administration of 
placebo in a large sample of patients with airflow 
obstruction. On factor analysis, these parameters 
clustered into three dimensions, expressing changes 
in flows, volumes, and dynamic hyperinflation.
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